Canopy Growth Corporation (CGC)
USD 2.83
(-7.21%)
USD 2.83
(-7.21%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 548.89 Million USD | -26.81% |
| 2022 | 749.99 Million USD | -49.72% |
| 2021 | 1.49 Billion CAD | -5.18% |
| 2020 | 1.57 Billion CAD | 176.44% |
| 2019 | 569.06 Million CAD | -32.44% |
| 2018 | 842.25 Million CAD | 12168.89% |
| 2017 | 6.86 Million CAD | -20.53% |
| 2016 | 8.63 Million CAD | 149.03% |
| 2015 | 3.46 Million CAD | 123.17% |
| 2014 | 1.55 Million CAD | 4328.59% |
| 2013 | 35.09 Thousand CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 408.08 Million USD | 13.22% |
| 2023 Q4 | 364.14 Million USD | -38.06% |
| 2023 Q3 | 587.91 Million USD | -16.16% |
| 2023 Q2 | 701.25 Million USD | -19.17% |
| 2023 Q1 | 867.54 Million USD | 15.67% |
| 2023 FY | 548.89 Million USD | -26.81% |
| 2022 Q1 | 1.26 Billion CAD | -15.22% |
| 2022 FY | 749.99 Million USD | -49.72% |
| 2022 Q4 | 749.99 Million USD | -0.02% |
| 2022 Q3 | 750.11 Million CAD | -27.32% |
| 2022 Q2 | 1.03 Billion CAD | -18.39% |
| 2021 Q3 | 1.59 Billion CAD | 5.35% |
| 2021 Q2 | 1.51 Billion CAD | -7.35% |
| 2021 Q4 | 1.49 Billion CAD | -6.71% |
| 2021 Q1 | 1.63 Billion CAD | 4.14% |
| 2021 FY | 1.49 Billion CAD | -5.18% |
| 2020 Q3 | 718.1 Million CAD | 37.98% |
| 2020 Q1 | 574.84 Million CAD | 1.02% |
| 2020 Q2 | 520.42 Million CAD | -9.47% |
| 2020 FY | 1.57 Billion CAD | 176.44% |
| 2020 Q4 | 1.57 Billion CAD | 119.07% |
| 2019 Q4 | 569.06 Million CAD | 6.15% |
| 2019 Q3 | 536.1 Million CAD | -9.19% |
| 2019 Q1 | 787.5 Million CAD | -6.5% |
| 2019 FY | 569.06 Million CAD | -32.44% |
| 2019 Q2 | 590.37 Million CAD | -25.03% |
| 2018 FY | 842.25 Million CAD | 12168.89% |
| 2018 Q4 | 842.25 Million CAD | 8.95% |
| 2018 Q2 | 6.7 Million CAD | -98.91% |
| 2018 Q3 | 773.04 Million CAD | 11426.0% |
| 2018 Q1 | 617.74 Million CAD | 8898.53% |
| 2017 Q2 | 7.95 Million CAD | -3.21% |
| 2017 Q4 | 6.86 Million CAD | -5.88% |
| 2017 FY | 6.86 Million CAD | -20.53% |
| 2017 Q1 | 8.22 Million CAD | -4.82% |
| 2017 Q3 | 7.29 Million CAD | -8.36% |
| 2016 Q2 | 6.36 Million CAD | 82.34% |
| 2016 FY | 8.63 Million CAD | 149.03% |
| 2016 Q4 | 8.63 Million CAD | 41.81% |
| 2016 Q3 | 6.09 Million CAD | -4.24% |
| 2016 Q1 | 3.48 Million CAD | 0.58% |
| 2015 Q4 | 3.46 Million CAD | -3.91% |
| 2015 Q2 | 3.39 Million CAD | 107.91% |
| 2015 FY | 3.46 Million CAD | 123.17% |
| 2015 Q1 | 1.63 Million CAD | -2.09% |
| 2015 Q3 | 3.61 Million CAD | 6.26% |
| 2014 Q1 | 1.55 Million CAD | 4595.19% |
| 2014 Q3 | 1.55 Million CAD | 0.0% |
| 2014 Q2 | - CAD | -100.0% |
| 2014 Q4 | 1.66 Million CAD | 7.37% |
| 2014 FY | 1.55 Million CAD | 4328.59% |
| 2013 Q3 | 35.09 Thousand CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 FY | 35.09 Thousand CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q4 | 33.1 Thousand CAD | -5.68% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Theratechnologies Inc. | 51.26 Million USD | -970.777% |
| Harrow Health, Inc. | 183.17 Million USD | -199.659% |
| Dynavax Technologies Corporation | 252.41 Million USD | -117.453% |
| Biofrontera Inc. | 804 Thousand USD | -68170.025% |
| Cronos Group Inc. | 1.55 Million USD | -35107.89% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -630809.195% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | -10.151% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -1505.414% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -120535.385% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -4193.53% |
| Radius Health, Inc. | 339.66 Million USD | -61.598% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| DURECT Corporation | 2.7 Million USD | -20214.249% |
| ProPhase Labs, Inc. | 10.25 Million USD | -5250.858% |
| Safety Shot Inc | 304.9 Thousand USD | -179919.153% |
| Phibro Animal Health Corporation | 458.28 Million USD | -19.77% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -468520.922% |
| Alvotech | 1.02 Billion USD | 46.594% |
| Assertio Holdings, Inc. | 38.51 Million USD | -1325.173% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -1553.485% |
| Rockwell Medical, Inc. | 8.29 Million USD | -6518.727% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -101728.453% |
| Procaps Group S.A. | 28.41 Million USD | -1832.034% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -4018.948% |
| SCYNEXIS, Inc. | 12.15 Million USD | -4414.277% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -4946.345% |
| Viatris Inc. | 16.18 Billion USD | 96.609% |
| OptiNose, Inc. | 611 Thousand USD | -89734.861% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -163264.793% |
| Tilray Brands, Inc. | 287.93 Million USD | -90.63% |
| PetIQ, Inc. | 437.82 Million USD | -25.369% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -101728.453% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -112.501% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Alimera Sciences, Inc. | 64.48 Million USD | -751.139% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | -12.027% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -406218.057% |
| Organogenesis Holdings Inc. | 60.74 Million USD | -803.599% |
| Journey Medical Corporation | 14.62 Million USD | -3653.871% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -7904.402% |
| Alpha Teknova, Inc. | 13.25 Million USD | -4042.261% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -76134.861% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | -355.473% |
| PainReform Ltd. | 30 Thousand USD | -1829536.667% |
| Cosmos Health Inc. | 3.03 Million USD | -17983.339% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -1575.492% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -8303.108% |
| Embecta Corp. | 1.62 Billion USD | 66.23% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 513.79 Million USD | -6.831% |
| Incannex Healthcare Limited | 210 Thousand USD | -261276.667% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -2441151.557% |
| Shineco, Inc. | 10.01 Million USD | -5379.413% |
| Procaps Group, S.A. | 28.41 Million USD | -1832.034% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | -77.251% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | -502.674% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 10.912% |
| Alvotech | 1.02 Billion USD | 46.594% |
| Hempacco Co., Inc. | 5.93 Million USD | -9154.61% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | -876.396% |
| Bright Green Corporation | 201.78 Thousand USD | -271920.438% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -9.44% |
| Kamada Ltd. | 7.43 Million USD | -7279.551% |
| Indivior PLC | 235.66 Million USD | -132.91% |
| Evoke Pharma, Inc. | 5 Million USD | -10877.82% |
| Flora Growth Corp. | 942 Thousand USD | -58168.684% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -2441151.557% |
| Evolus, Inc. | 120.35 Million USD | -356.045% |
| HUTCHMED (China) Limited | 48.18 Million USD | -1039.038% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 6.841% |
| Akanda Corp. | 2.49 Million USD | -21880.654% |